Critical appraisal:Rotolo F, Dunant A, Le Chevalier T, Pignon JP, Arriagada R, IALT Collaborative Group 2014 1
- Article
- Rotolo F, Dunant A, Le Chevalier T, Pignon JP, Arriagada R, IALT Collaborative Group. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach. Ann Oncol 2014 Nov;25(11):2162-6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25193990.
- Assigned to
- User:Shawgi.sukumaran
- Topic area
- Guidelines:Lung cancer/Treatment/Non-small-cell stage II operable
- Clinical question
- Study design
- randomised controlled trial
- Level of Evidence
- II
Section below only relevant for Cancer Council Project Officer
Critical Appraisal
Rotolo F, Dunant A, Le Chevalier T, Pignon JP, Arriagada R, IALT Collaborative Group. Adjuvant cisplatin-based chemotherapy in nonsmall-cell lung cancer: new insights into the effect on failure type via a multistate approach. Ann Oncol 2014 Nov;25(11):2162-6 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25193990.
Key Facts
randomised controlled trial
This study aimed to look at long term mortality data from subjects on the IALT study
1687
it reports that long term non-cancer mortality was higher in patients who received chemotherapy arm compared to the control
Hazard Ratio of non cancer mortality in the Treated arm compared to controls HR 3.6 (95% CI 2.2-5.9, P<0.001)
The conclusion were based on a small total number of events
no
Evidence ratings
II
Moderate risk of bias | Comments: Please replace this text and include any additional comments in regards to your risk of bias rating |
4 | Reason for decision: Please replace this text and briefly describe the reasons for your rating |
1 | Additional comments: Please replace this text and briefly describe the reasons for your rating |
Long term side effects including the potential increased mortality risks should be taken into consideration while making clinical decisions regarding adjuvant chemotherapy